| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
2'-O-MB-cAMP sodium targets cAMP-dependent protein kinase (PKA), the primary effector of cAMP signaling. As a cell-permeable cAMP analog, it activates PKA by binding to its regulatory subunits and releasing the catalytic subunits. The compound is more resistant to hydrolysis by phosphodiesterases compared to cAMP, resulting in prolonged activation of PKA. Its targets include downstream substrates of PKA involved in various cellular processes.
|
|---|---|
| ln Vitro |
2'-O-MB-cAMP sodium activates cAMP-dependent protein kinase (PKA) in vitro. The compound is more resistant to hydrolysis by phosphodiesterases compared to cAMP, resulting in prolonged activation of PKA. As a cell-permeable cAMP analog, it can enter cells and activate PKA signaling pathways. These in vitro findings support its applications in studying cAMP signaling and PKA-mediated cellular processes.
|
| ln Vivo |
In vivo studies of 2'-O-MB-cAMP sodium are limited as the compound is primarily used as a research tool for in vitro and cellular studies. Its cell-permeable nature and resistance to phosphodiesterase hydrolysis make it useful for studying cAMP signaling in vivo. However, comprehensive in vivo pharmacological studies specifically targeting 2'-O-MB-cAMP sodium are not well documented. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme assays for 2'-O-MB-cAMP sodium typically involve testing its ability to activate PKA. PKA activity is measured using appropriate substrates and detection methods. The compound's resistance to phosphodiesterase hydrolysis is assessed by measuring its stability in the presence of phosphodiesterases. The compound's purity and identity are confirmed using analytical chemistry methods such as high-performance liquid chromatography and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for 2'-O-MB-cAMP sodium involve culturing cells to evaluate its effects on cAMP signaling. Cells are treated with varying concentrations of the compound and PKA activation is assessed by measuring phosphorylation of downstream targets. Cell viability is assessed using standard assays. The compound's ability to activate cAMP-responsive gene expression is evaluated using reporter gene assays. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for 2'-O-MB-cAMP sodium would be conducted to evaluate its effects on cAMP signaling pathways. Animals would be administered the compound and PKA activation assessed in target tissues. Parameters assessed would include phosphorylation of PKA substrates and downstream signaling effects. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 2'-O-MB-cAMP sodium reflect its nature as a cell-permeable cAMP analog. It has a molecular formula of C15H20N5NaO8P. As a charged molecule, it has limited ability to cross cell membranes without modification; however, the butyryl modification enhances cell permeability. The compound is resistant to phosphodiesterase hydrolysis, resulting in prolonged activity. Complete pharmacokinetic profiling would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 2'-O-MB-cAMP sodium has been evaluated in the context of its use as a research chemical. As a cAMP analog, it may have biological effects that should be carefully evaluated. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References |
[1]. Russell PN, et al. Identification of butyryl derivatives of cyclic nucleotides by positive ion fast atom bombardment mass spectrometry and mass-analysed ion kinetic energy spectrometry. Organic Mass Spectrometry. August 1989.
|
| Additional Infomation |
2'-O-MB-cAMP sodium (CAS# 55443-13-5) is also known as 2'-O-Monobutyryl cyclic AMP sodium. It is a cell-permeable cAMP analog that activates cAMP-dependent protein kinase (PKA). The compound is more resistant to hydrolysis by phosphodiesterases compared to cAMP, making it a potent and long-lasting activator of PKA. It is used in research applications for studying cAMP signaling pathways.
|
| Molecular Formula |
C14H17N5NAO7P
|
|---|---|
| Molecular Weight |
421.28
|
| Exact Mass |
421.076
|
| CAS # |
55443-13-5
|
| PubChem CID |
16219622
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.553
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
627
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC(=O)OC1C2C(COP(=O)(O2)O)OC1N3C=NC4=C(N=CN=C43)N.[Na]
|
| InChi Key |
QSEXPGXXMNULPU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H18N5O7P.Na/c1-2-3-8(20)25-11-10-7(4-23-27(21,22)26-10)24-14(11)19-6-18-9-12(15)16-5-17-13(9)19;/h5-7,10-11,14H,2-4H2,1H3,(H,21,22)(H2,15,16,17);
|
| Chemical Name |
sodium [(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (237.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3737 mL | 11.8686 mL | 23.7372 mL | |
| 5 mM | 0.4747 mL | 2.3737 mL | 4.7474 mL | |
| 10 mM | 0.2374 mL | 1.1869 mL | 2.3737 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
